ClinicalTrials.gg

Program

brivaracetam

Also written as “Brivaracetam”, “Brivaracetam Film-coated tablet” and “Brivaracetam oral solution”.

Its studies are mostly in Epilepsy · Epilepsy, Absence · Epilepsies, Partial · Myoclonus · Seizures, led by 4 companies.

Furthest: phase 3, since Sep 6, 200542 company-led studies, 3 open or runningNext primary completion: Nov 16, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB392 open or runningphase 3since Sep 6, 2005Sep 6, 2005Nov 16, 2029phase 3 · NCT06315322
Overseas Pharmaceuticals10 open or runningphase 1since Nov 11, 2022Nov 11, 2022none ahead
Qingfeng Pharmaceutical Group10 open or runningphase 3since Apr 17, 2026Apr 17, 2026none ahead
Sino Biopharmaceutical11 open or runningphase 1since Dec 23, 2024Dec 23, 2024none ahead

Also a collaborator on its studies: pra-health-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 28 studies since Sep 6, 2005.

  1. Jul 31, 2017Phase 3 study in EpilepsyUCB · NCT03250377 · 207 enrolled · China, Japan
  2. Oct 25, 2017Phase 3 study in EpilepsyUCB · NCT03325439 · 9 enrolled · Belgium, Czechia, France and more
  3. Jan 12, 2018Phase 2 study in EpilepsyUCB · NCT03405714 · 50 enrolled · United States, Czechia, Germany and more
  4. Sep 20, 2018Phase 3 study in EpilepsyUCB · NCT03685630 · 10 enrolled · Japan
  5. Dec 7, 2020Phase 3 study in Epilepsy, AbsenceUCB · NCT04666610 · 154 enrolled · United States, Georgia, Italy and more
  6. Jan 14, 2021Phase 3 study in EpilepsyUCB · NCT04715646 · 70 planned · United States, Belgium, Czechia and more
  7. May 6, 2021Phase 1 study in EpilepsyUCB · NCT04882540 · 12 enrolled · China
  8. Oct 25, 2021Phase 3 study in Epilepsy, AbsenceUCB · NCT05109234 · 84 enrolled · United States, Georgia, Italy and more
  9. Mar 14, 2022Phase 1 study in Healthy Study ParticipantsUCB · NCT05315947 · 24 enrolled · Japan
  10. Nov 11, 2022Overseas Pharmaceuticals's first study: phase 1 study in SeizuresNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT05622370 · 12 enrolled · China
  11. Mar 8, 2024Phase 1 study in Healthy Study ParticipantsUCB · NCT06312566 · 64 enrolled · Japan
  12. Mar 11, 2024Phase 3 study in Epilepsy, AbsenceUCB · NCT06315322 · 70 enrolled · United States, Georgia, Italy and more
  13. Dec 23, 2024Sino Biopharmaceutical's first study: phase 1 study in EpilepsyNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06762743 · 60 planned · China
  14. Apr 17, 2026Qingfeng Pharmaceutical Group's first study: phase 3 study in Epilepsies, PartialNew to Qingfeng Pharmaceutical GroupQingfeng Pharmaceutical Group · NCT07563634 · 141 enrolled · China

Ahead

  1. Nov 16, 2029Primary completion: phase 3 study in Epilepsy, AbsenceUCB · NCT06315322
  2. Jul 8, 2030Primary completion: phase 3 study in EpilepsyUCB · NCT04715646

TargetBeta

SV2A →read by rule
“Synaptic vesicle glycoprotein 2A modulator”ChEMBL 37, by rule

Other programs on SV2A

ProgramCompanyFurthest phaseStudies
LevetiracetamruleUCBphase 473

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07563634Epilepsies, Partial · China3CompletedQingfeng Pharmaceutical GroupMay 21, 2024141
NCT06762743Epilepsy · China1By invitationSino BiopharmaceuticalDec 31, 202460
NCT06315322Epilepsy, Absence · United States, Georgia, Italy and more3Active, not recruitingUCBNov 16, 202970
NCT06312566Healthy Study Participants · Japan1CompletedUCBJun 4, 202464
NCT05622370Seizures · China1UNKNOWNOverseas PharmaceuticalsMar 30, 202312
NCT05315947Healthy Study Participants · Japan1CompletedUCBMay 13, 202224
NCT05109234Epilepsy, Absence · United States, Georgia, Italy and more3CompletedUCBMar 18, 202584
NCT04882540Epilepsy · China1CompletedUCBJun 8, 202112
NCT04715646Epilepsy · United States, Belgium, Czechia and more3RecruitingUCBJul 8, 203070
NCT04666610Epilepsy, Absence · United States, Georgia, Italy and more3CompletedUCBJul 7, 2026154
NCT03685630Epilepsy · Japan3CompletedUCBMar 27, 202110
NCT03405714Epilepsy · United States, Czechia, Germany and more2CompletedUCBNov 4, 202050
NCT03325439Epilepsy · Belgium, Czechia, France and more3TerminatedUCBSep 3, 20209
NCT03250377Epilepsy · China, Japan3CompletedUCBDec 24, 2024207
NCT03083665Epilepsy · China, Japan, Malaysia and more3CompletedUCBJun 30, 2022449
NCT03021018Epilepsy · United States2CompletedUCBApr 27, 201846
NCT02602860Healthy Volunteers · United States1CompletedUCBSep 201713
NCT02088957Nonconvulsive Electrographic Seizures · United States2TerminatedUCBOct 20141
NCT01728077Epilepsy · United States, France, Germany and more3CompletedUCBAug 201626
NCT01710670Healthy Volunteers · Netherlands1CompletedUCBNov 201218
NCT01653262Epilepsy · United States, France, Germany and more3CompletedUCBNov 201329
NCT01405508Epilepsy · United States, Czechia, Germany and more3CompletedUCBJul 2012105
NCT01364597Epilepsy · United States, Belgium, Czechia and more3CompletedUCBFeb 3, 2022257
NCT01339559Epilepsy · United States, Austria, Belgium and more3CompletedUCBApr 18, 2019767
NCT01261325Epilepsy · United States, Austria, Belgium and more3CompletedUCBMay 2014768
NCT00761774Epilepsy · United States, Australia, Belgium and more3CompletedUCBMar 2017108
NCT00736931Epilepsy · United States1CompletedUCBOct 200820
NCT00699283Epilepsy · United States, France, Germany and more3TerminatedUCBMar 201062
NCT00698581Epilepsy · United States, Australia, Belgium and more3TerminatedUCBJan 201088
NCT00504881Epilepsy · Austria, Belgium, Czechia and more3CompletedUCBNov 2008480
NCT00490035Epilepsy · Belgium, Finland, France and more3CompletedUCBFeb 2009399
NCT00464269Epilepsy · United States, Australia, Brazil and more3CompletedUCBDec 2008400
NCT00426673Epilepsy · United States1CompletedUCBJun 200615
NCT00422422Epilepsy · United States, Belgium, Czechia and more2CompletedUCBMar 2013100
NCT00401648Epilepsy · France, Germany2CompletedUCBJun 200320
NCT00368251Unverricht-Lundborg Syndrome · United States, Canada, Finland and more3CompletedUCBJan 200856
NCT00357669Unverricht-Lundborg Syndrome · Finland, France, Italy and more3CompletedUCBOct 200750
NCT00175929Epilepsies, Partial · Belgium, Czech Republic, Finland and more2CompletedUCBMar 2006157
NCT00175916Epilepsy · United States, Austria, Belgium and more3CompletedUCBMay 2019853
NCT00175825Epilepsy · United States, Brazil, India and more2CompletedUCBJun 29, 2006210
NCT00160667Neuralgia, Postherpetic · Belgium, Bulgaria, Czechia and more2CompletedUCBJan 5, 2006152
NCT00150800Epilepsy · United States, Australia, Brazil and more3CompletedUCBSep 2017668

How it is read

Names in the registry

  • “Brivaracetam”, 33 entries
  • “brivaracetam”, 3 entries
  • “Brivaracetam Film-coated tablet”, 2 entries
  • “Brivaracetam oral solution”, 2 entries
  • “Brivaracetam 25 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.